Results 171 to 180 of about 5,401 (225)

Successful therapy of ulcerative morphea with topical application of pimecrolimus

Journal of the European Academy of Dermatology and Venereology, 2022
Dear Editor, A 65yearold female patient presented to our department with ulcers of both pretibial lower legs and a slightly reduced general and normal nutritional condition.
M. Moelleken, Britta Kießler, E. Hadaschik, J. Dissemond   +3 more
semanticscholar   +1 more source

Pimecrolimus – an anti-inflammatory drug targeting the skin

Experimental Dermatology, 2004
Pimecrolimus is the most recent member of calcineurin inhibitors available for the therapy for inflammatory skin diseases. It targets T-cells and mast cells and inhibits the production and release of cytokines and other inflammatory mediators, as well as
Martin Steinhoff, M Grassberger, T A Luger   +2 more
exaly   +1 more source

Topical treatment of eczematous external otitis involving the ear canal: long-term results of a trial comparing pimecrolimus 1 per cent versus clobetasone butyrate 0.05 per cent

Journal of Laryngology and Otology, 2022
Background Eczematous external otitis is a common chronic condition that can have a significant impact on the life of sufferers, causing constant discomfort and pruritus, and leading to sleep deprivation. Treatment is based on the use of topical steroids,
Zsofia Nemeth, E. Verga, Roberto Verdolini   +2 more
semanticscholar   +1 more source

Pimecrolimus for psoriasis

Expert Opinion on Pharmacotherapy, 2013
Pimecrolimus is a calcineurin inhibitor which has a role in the treatment of psoriasis. However, it remains an off-license treatment, despite its potential use in patients with treatment-resistant psoriasis or in those who have had multiple adverse effects to other therapies.This review covers the efficacy and role of both topical and oral Pimecrolimus
Ayer, J, Young, HS.
openaire   +3 more sources

Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children

Pediatrics, 2002
OBJECTIVE: Pimecrolimus cream (SDZ ASM 981), a nonsteroid inhibitor of inflammatory cytokines, is effective in atopic dermatitis (AD). We assessed whether early treatment of AD signs/symptoms with pimecrolimus could influence long-term outcome by ...
Kim A. Papp, Ulrich Wahn, Carle Paul
exaly   +2 more sources

The efficacy and safety of pimecrolimus 1% cream vs. sertaconazole 2% cream in the treatment of patients with facial seborrhoeic dermatitis: a randomized blinded trial

Clincal and Experimental Dermatology, 2021
Facial seborrhoeic dermatitis (FSD) is a chronic inflammatory skin disorder characterized by remission and exacerbation episodes. In most cases, FSD requires long‐term treatment.
M. Azizzadeh, Daryoush Pahlevan, B. Bagheri   +2 more
semanticscholar   +1 more source

Pimecrolimus

Reactions Weekly, 2010
  +7 more sources

Off-label Uses of Topical Pimecrolimus

Journal of Cutaneous Medicine and Surgery, 2019
Pimecrolimus is a topical calcineurin inhibitor currently approved for second-line use in the management of mild-to-moderate atopic dermatitis in patients age 2 years and older.
M. Ladda, V. Sandhu, A. Ighani, J. Yeung
semanticscholar   +1 more source

Pimecrolimus

Reactions Weekly, 2007
  +6 more sources

Pimecrolimus (Novartis).

IDrugs : the investigational drugs journal, 2003
Pimecrolimus, an ascomycin macrolactam derivative, is an inhibitor of T-cell and mast cell activation under development by Novartis for the potential treatment of psoriasis and allergic dermatitis. Novartis is developing both topical and oral formulations of the compound.
openaire   +2 more sources